XBT Provider announces plans for Ether Tracker One and Ether Tracker Euro following Ethereum’s Merge
September 14, 2022 | STOCKHOLM, Sweden - XBT Provider AB (Publ) ( the "Issuer") has today announced details of the potential effects of Ethereum’s upcoming merge on two of its ether-based securities.
The affected securities are listed below:
Ether Tracker One
Nasdaq Ticker: ETHEREUM XBT
Bloomberg Ticker: COINETH:SS
Ether Tracker Euro
Nasdaq Ticker: ETHEREUM XBTE
Bloomberg Ticker: COINETHE:SS
The Issuer has been closely following the developments in the Ethereum protocol, with respect to both the proposed move (the “Merge”) to a Proof of Stake consensus network (the “ETHPoS”) as well as the proposed fork (the “Fork”) of the existing Proof of Work consensus network (the “ETHPoW”). As a result of the Fork, the Issuer understands that a new Digital Currency (“ETHW”) will be created and distributed pro rata to all holders of the existing Ether Digital Currency (ETH).
Although the Issuer, in accordance with the Prospectus, has no legal obligation to distribute forked coins to certificate holders, it nevertheless seeks to return the value creation to Certificate Holders where possible. Accordingly, the Issuer has developed the following (long-standing) policy on forks:
- Forks eligible for the plan will be selected according to the available information of each separate fork, at the Issuer's discretion, with a focus on the viability and value of the new token.
- The forks will be distributed to certificate holders bi-annually.
- Critically, the Issuer will provide a corporate action date, in which certificate holders in possession of the certificates (as at the corporate action date) will be eligible to receive a cash distribution accumulated by forks during the preceding half-year period.
- Only owners of certificate by Euroclear definition will be paid and they will distribute to their underlying clients, sometimes multiple levels.
- Once owners are paid, the responsibility is no longer within the firm for good execution.
- The Issuer will announce a corporate action date three (3) weeks in advance of each bi-annual fork distribution.
- The corporate action date is designed to allow the Issuer to capture a snapshot of the registered certificate holders at the point of the corporate action. These certificate holders will be eligible to receive proceeds the Issuer has collected during the preceding 6 months.
The Issuer notes that the market for ETHW may experience significant price volatility during the Merge and that the new protocol for ETHW may experience risks associated with the stability of the technology underpinning the protocol as well as risks to the adoption of ETHW among exchanges and custodians. The Issuer will endeavour to sell ETHW and distribute the proceeds to Certificate Holders in the event the proceeds are material and the protocol is stable, but the Issuer can make no guarantees as to its ability to do this..
About XBT Provider
XBT Provider AB (Publ) (“XBT Provider”), a CoinShares company, is the Swedish-domiciled issuer of the Bitcoin Tracker One (SE0007126024), Bitcoin Tracker Euro (SE0007525332), Ether Tracker One (SE0010296574), Ether Tracker Euro (SE0010296582), series of certificates (collectively, the “Certificates”) which are designed to synthetically track the performance of the price of the relevant underlying crypto-asset, bitcoin or ether, (in Swedish Kronor or Euro, respectively), less a fee component.
In 2015, Bitcoin Tracker One became the first bitcoin-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. In 2017, Ether Tracker One became the first ether-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. The Certificates are available and traded in the same manner as any other share or instrument listed on their respective exchanges.
XBT Provider’s Prospectus is approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the Certificates are governed by Swedish law. XBT Provider is not a licensed financial advisor. The views presented in this release are the opinions of the Board of XBT Provider and no other party. Bitcoin and ether, are volatile assets and their prices (and the price of securities that are referenced to them) can move quickly, positively or negatively. Prospective investors in the Certificates should carefully consider the suitability of such an investment and whether they have sufficient financial resources in order to be able to bear the risks associated therewith and, in connection with such a determination, should carefully read XBT Provider’s latest Prospectus (including, in particular, the risk warnings set out therein). The Certificates do not confer on the holders thereof any claim to or against the relevant underlying crypto-asset to which they are referenced. The value and any payment due under the Certificates will be affected by the exchange rate between the US Dollar and the Euro or, as the case may be, between the US Dollar and the Swedish Kronor. Any returns upon the Certificates will not be the same as the returns which a direct investment of an equivalent sum in the relevant underlying crypto-asset could produce. The Certificates are non-equity linked, non-principal protected, unsecured and unsubordinated and do not bear interest.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Azerion simplifies loan structures between Azerion and Principion11.12.2023 07:30:00 CET | Press release
Amsterdam, 11 December 2023 – Azerion Group N.V. ("Azerion") announces that it has today entered into an agreement with Principion Holding B.V. ("Principion") to simplify Azerion's loan structure by settling several loans outstanding between Azerion and Principion (the "Loan Settlement"). The objectives of the Loan Settlement are to simplify Azerion’s capital structure by setting off mutually outstanding unsecured liabilities, whilst at the same time providing Azerion with security against remaining balances. The Loan Settlement also provides Azerion the ability to use any ordinary shares in the capital of Azerion (the "Shares") to be acquired through the Loan Settlement mechanism for value creating purposes for all shareholders without the issuance of new Shares. The Loan Settlement has been approved by Azerion's management board and supervisory board. As at the date of this press release, the aggregate amount due and outstanding under the loans provided by (i) Principion to Azerion i
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®11.12.2023 07:30:00 CET | Press release
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced data from a real-world case series evaluating treatment of three complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023. Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%. There were no imp
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)11.12.2023 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9 Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meeting Iptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across four investigational indications10-14 Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period
Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs11.12.2023 07:00:00 CET | Press release
Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network 11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The Nokia platform helps operators monetize their 5G network assets beyond pure connectivity. It provides application developers with tools such as Software Devel